Workflow
Why Tempus AI Stock Is Plunging This Week

Core Insights - Tempus AI stock experienced a significant 161% gain since the beginning of the year, but recently faced a decline following a well-known investor's decision to reduce her position in the stock [1][2] - The stock fell 12.4% from the end of last Friday's trading to the close of Thursday's market session [2] - Ark Invest reduced its position in Tempus AI by 62,352 shares, valued at approximately $5.2 million, impacting its weighting in the ARK Innovation ETF [4] Company Developments - Tempus AI received 510(k) clearance from the U.S. FDA for its RNA-based Tempus xR IVD device, aimed at supporting drug development programs [5] - Despite the reduction in the ARK Innovation ETF, Tempus AI remains the largest position in the ARK Genomic Revolution ETF, with a 10.7% weighting [5][6] Investor Sentiment - The reduction by Ark Invest may cause concern among investors, but the stock's significant position in the ARK Genomic Revolution ETF indicates continued support [6] - Ark Invest's trading strategy often involves buying and selling stocks, suggesting potential future purchases of Tempus AI if the stock price declines further [7]